Venous Thromboembolism in IBD Not Linked to Increased Thrombophilia
Researchers investigated whether thrombophilia in patients with IBD significantly contributes to developing venous thromboembolic events.
Researchers investigated whether thrombophilia in patients with IBD significantly contributes to developing venous thromboembolic events.
A study sought to determine whether overweight/obesity is a factor in the development of thrombosis in cancer patients with peripherally inserted central catheters.
Direct oral anticoagulants reduce recurrent VTE events by 41 percent, with no significant increase in major bleeding, compared to dalteparin
Investigators sought to determine the risk and 1-year burdens for several cardiovascular outcomes in patients who survived acute COVID-19 infection.
Standardized incidence ratio was 3.0 during first year of follow-up after VTE and decreased to 1.5 during subsequent years
The updated CHEST guideline on antithrombotic therapy for VTE includes 4 new PICO questions as well as updated recommendations based on newer evidence.
Is there a significant relationship between obstructive impairment and the low forced expiratory volumes frequently seen in patients with CTEPH?
Researchers investigated whether a mobile health technology program for older adults with AF and multimorbidity would help decrease AF-related adverse events.
Investigators examined the incidence of and risk factors for venous thromboembolism in pediatric patients with IBD compared with the general pediatric population.
A new oral suspension formulation of Xarelto has also been approved by the FDA.